Quantcast
Last updated on April 16, 2014 at 21:24 EDT

Latest Thrombectomy Stories

2012-03-26 12:21:56

Administration of a bolus dose of the anticoagulant drug abciximab into the coronary artery involved in causing a certain type of heart attack among patients who were undergoing a percutaneous coronary intervention and also receiving another anticoagulant resulted in reduction in the size of damage to the heart muscle at 30 days, while a procedure that involved use of a catheter to remove the blood clot blocking that coronary artery did not produce these results, according to a study...

2011-05-06 12:48:00

MOUNTAIN VIEW, Calif., May 6, 2011 /PRNewswire/ -- Hotspur Technologies, Inc. announced today that it has received CE Mark approval for the IQCath Balloon Dilatation Catheter, allowing the company to introduce the novel technology to markets outside of the United States. The IQCath catheter utilizes Hotspur's groundbreaking technology to combine multiple functions into a single device that can potentially make procedures to open blocked blood vessels more efficient and cost-effective...

2010-12-07 08:28:00

TORONTO, Dec. 7, 2010 /PRNewswire/ -- Millennium Research Group (MRG), the global authority on medical technology market intelligence, will soon release their latest data on the US clot management device market. MRG's US Markets for Clot Management Devices 2011 report provides important insight into the device-based treatments of deep vein thrombosis and the complex competitive dynamics of medical device manufacturers in this field. The report also provides market analyses for devices...

2010-02-09 07:30:00

SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leading developer and manufacturer of precision intravascular therapy guidance tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, announced today that it has acquired the Xtract(TM) Thrombus Aspiration Catheter device line from Lumen Biomedical. Volcano became the exclusive global distributor of the Xtract(TM) catheter in May 2009. This acquisition reinforces...

2009-06-25 07:07:00

WALTHAM, Mass., June 25 /PRNewswire/ -- According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, pharmacomechanical thrombectomy (PMT) procedure adoption will accelerate over the next five years due to growing physician interest in treating deep vein thrombosis (DVT). Although the ATTRACT (Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis) trial, which will compare catheter-directed thrombolysis (CDT)...

2009-06-23 06:30:00

- KENSEY NASH EARNS $1.5M MILESTONE UNDER SPECTRANETICS AGREEMENT - EXTON, Pa., June 23 /PRNewswire-FirstCall/ -- Kensey Nash Corporation (Nasdaq: KNSY) today announced that the ThromCat(R) XT Thrombectomy Catheter System has been granted CE Marking approval which allows for the sale of the product throughout the European Economic Area (EEA). The ThromCat XT System, a mechanical thrombectomy catheter designed to remove thrombus (blood clots) from a patient, is indicated for use in both the...

2009-05-18 07:00:00

Product Launch Highlights Volcano's Presence at 2009 EuroPCR SAN DIEGO, May 18 /PRNewswire-FirstCall/ -- Volcano Corporation (Nasdaq: VOLC), a leader in the development, manufacturing and sales of products for the diagnosis and treatment of coronary and peripheral artery disease, today announced an exclusive worldwide distribution agreement to initiate the formal launch of the Xtract(TM) thrombus aspiration catheter, manufactured by Lumen Biomedical. The Xtract(TM) thrombus aspiration...

2009-01-07 07:07:00

WALTHAM, Mass., Jan. 7 /PRNewswire/ -- According to Millennium Research Group's (MRG's) US Markets for Plaque and Thrombus Management Devices 2009 report, the thrombectomy device market, including both aspiration and mechanical devices, is expected to grow to more than $875 million by 2013. The number of aspiration procedures performed in coronary indications is expected to more than double its 2007 value by the end of 2009. Coronary thrombectomies grew significantly in 2008 due...

2008-09-22 15:00:14

MEDRAD Interventional/Possis, the new endovascular-focused division of MEDRAD, INC., today announced that it is a sponsor of the ATTRACT trial which will evaluate the long-term benefits of using the company's AngioJet(R) Rheolytic(TM) Thrombectomy System in combination with clot-softening drugs to provide more rapid endovascular treatment of Deep Vein Thrombosis (DVT). One of the most dangerous circulatory diseases is also one of the least recognized. In the U.S., as many as 1 million...